Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results

Rhea-AI Summary

Fate Therapeutics, Inc. (NASDAQ: FATE) will host a conference call on November 5, 2020, at 5:00 p.m. ET to discuss its third quarter 2020 financial results and provide a corporate update.

Participants can join by calling (877) 303-6235 domestically or (631) 291-4837 internationally using conference ID 1060606.

The live audio webcast will be accessible via the company's website, with an archived version available two hours post-event.

SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 5:00 p.m. ET to report its third quarter 2020 financial results and provide a corporate update.

In order to participate in the conference call, please dial (877) 303-6235 (domestic) or (631) 291-4837 (international) and refer to conference ID 1060606. To listen only, please dial (877) 638-9571 (domestic) or (760) 666-3586 (international) and refer to conference ID 1060606. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

When is Fate Therapeutics' Q3 2020 earnings call?

Fate Therapeutics' Q3 2020 earnings call is scheduled for November 5, 2020, at 5:00 p.m. ET.

How can I participate in the Fate Therapeutics earnings call?

To participate in the Fate Therapeutics earnings call, dial (877) 303-6235 for domestic calls or (631) 291-4837 for international calls, and use conference ID 1060606.

Where can I listen to the Fate Therapeutics earnings call?

The earnings call can be listened to live on the Fate Therapeutics website under 'Events & Presentations' or accessed as an archived version approximately two hours after the event.